Sagimet Biosciences Inc. (SGMT )

Currency in USD Disclaimer
$9.14 +$1.81 (24.69%)
Open 10/27/2025
$7.69
$9.45
$1.73
$11.41

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SGMT
  • Company Sagimet Biosciences Inc.
  • Price $9.14
  • Changes Percentage 24.69
  • Change 1.81
  • Day Low $7.69
  • Day High $9.45
  • Year High $11.41
  • Year Low $1.73
  • Market Cap $283,350,136
  • Price Avg 50 EMA (D) $7.25
  • Price Avg 200 EMA (D) $5.74
  • Exchange NASDAQ
  • Volume 2,534,629
  • Average Volume 598,512
  • Open $7.7
  • Previous Close $7.33
  • EPS -1.86
  • PE -4.91
  • Earnings Announcement 2025-11-13 12:30:00
  • Shares Outstanding $31,001,109

Company brief: SAGIMET BIOSCIENCES INC. (SGMT )

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SGMT Corporation News

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 at 11:00 am ET

globenewswire.com -- Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announce...

Income Statement